(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 41.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Axsome Therapeutics's revenue in 2025 is $495,033,000.On average, 10 Wall Street analysts forecast AXSM's revenue for 2025 to be $31,264,728,749, with the lowest AXSM revenue forecast at $29,461,837,925, and the highest AXSM revenue forecast at $32,436,764,974. On average, 10 Wall Street analysts forecast AXSM's revenue for 2026 to be $48,296,355,769, with the lowest AXSM revenue forecast at $40,619,810,418, and the highest AXSM revenue forecast at $53,756,376,871.
In 2027, AXSM is forecast to generate $70,501,369,750 in revenue, with the lowest revenue forecast at $54,262,876,964 and the highest revenue forecast at $93,159,090,021.